Targeted inhibition of cyclic AMP phosphodiesterase-4 promotes brain tumor regression

Clinical Cancer Research

Volumn 14, Issue 23, 2008, Pages 7717-7725

  Goldhoff, Patricia ^a   Warrington, Nicole M ^a   Limbrick Jr , David D ^a   Hope, Andrew ^a   Woerner, B Mark ^a   Jackson, Erin ^a   Perry, Arie ^a   Piwnica Worms, David ^a   Rubin, Joshua B ^a,b  

^a ST LOUIS CHILDREN S HOSPITAL   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IVA1; ROLIPRAM; TEMOZOLOMIDE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DACARBAZINE; DRUG DERIVATIVE; PHOSPHODIESTERASE INHIBITOR;

ADOLESCENT; ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; COMPUTER ASSISTED RADIOTHERAPY; CONTROLLED STUDY; ENZYME INHIBITION; EPENDYMOMA; FEMALE; GENE OVEREXPRESSION; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MEDULLOBLASTOMA; MENINGIOMA; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OLIGODENDROGLIOMA; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SURVIVAL TIME; TISSUE DISTRIBUTION; TUMOR GROWTH; TUMOR REGRESSION; TUMOR XENOGRAFT; ANIMAL; BRAIN TUMOR; DRUG SCREENING; ENZYMOLOGY; IMMUNOHISTOCHEMISTRY; METABOLISM; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; TUMOR CELL LINE; WESTERN BLOTTING;

ADOLESCENT; ADULT; AGED; ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; BRAIN NEOPLASMS; CELL LINE, TUMOR; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; DACARBAZINE; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MIDDLE AGED; PHOSPHODIESTERASE INHIBITORS; ROLIPRAM; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 59449107942     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0827     Document Type: Article

References (42)

1. DeAngelis LM. Chemotherapy for brain tumors-a new beginning. N Engl J Med 2005;352:1036-8.
2. Wen PY, Kesari S, Drappatz J. Malignant gliomas: strategies to increase the effectiveness of targeted molecular treatment. Expert Rev Anticancer Ther 2006;6:733-54.
3. Yang L, Jackson E, Woerner BM, Perry A, Piwnica- Worms D, Rubin JB. Blocking CXCR4-mediated cyclic AMP suppression inhibits brain tumor growth in vivo. Cancer Res 2007;67:651-8.
4. Marko D, Pahlke G, Merz KH, Eisenbrand G.Cyclic 3′, 5′-nucleotide phosphodiesterases: potential targets for anticancer therapy. Chem ResToxicol 2000;13: 944-8.
5. Houslay MD, Adams DR. PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. Biochem J 2003;370:1-18.
6. Lynch MJ, Hill EV, Houslay MD. Intracellular targeting of phosphodiesterase-4 underpins compartmentalized cAMP signaling. Curr Top Dev Biol 2006;75:225-59.
7. 2-adrenergic receptor to activation of ERK in HEK293B2 cells. J Biol Chem 2005;280:33178-89.
8. McCahill A, McSorleyT, Huston E, et al. In resting COS1 cells a dominant negative approach shows that specific, anchored PDE4 cAMP phosphodiesterase isoforms gate the activation, by basal cyclic AMP production, of AKAP-tethered protein kinaseAtype II located in the centrosomal region. Cell Signal 2005;17:1158-73.
9. Jin SL, Lan L, Zoudilova M, Conti M. Specific role of phosphodiesterase 4B in lipopolysaccharide-induced signaling in mouse macrophages. J Immunol 2005; 175:1523-31.
10. Drees M, Zimmermann R, Eisenbrand G. 3′, 5′- Cyclic nucleotide phosphodiesterase in tumor cells as potential target for tumor growth inhibition. Cancer Res 1993;53:3058-61.
11. Merz KH, Marko D, Regiert T, Reiss G, Frank W, Eisenbrand G. Synthesis of 7-benzylamino-6-chloro- 2-piperazino-4-pyrrolidinopteridine and novel derivatives free of positional isomers. Potent inhibitors of cAMP-specific phosphodiesterase and of malignant tumor cell growth. J Med Chem 1998;41:4733-43.
12. McEwan DG, Brunton VG, Baillie GS, Leslie NR, Houslay MD, Frame MC. Chemoresistant KM12C colon cancer cells are addicted to low cyclic AMP levels in a phosphodiesterase 4-regulated compartment via effects on phosphoinositide 3-kinase. Cancer Res 2007;67:5248-57.
13. Chen TC, Wadsten P, Su S, et al. The type IV phosphodiesterase inhibitor Rolipram induces expression of the cell cycle inhibitors p21(Cip1) and p27(Kip1), resulting in growth inhibition, increased differentiation, and subsequent apoptosis of malignant A-172 glioma cells. Cancer Biol Ther 2002;1:268-76.
14. Sullivan M, Rena G, Begg F, Gordon L, Olsen AS, Houslay MD. Identification and characterization of the human homologue of the short PDE4A cAMP- specific phosphodiesterase RD1 (PDE4A1) by analysis of the human HSPDE4A gene locus located at chromosome 19p13.2. Biochem J 1998;333: 693-703.
15. Shakur Y, Pryde JG, Houslay MD. Engineered deletion of the unique N-terminal domain of the cyclic AMP-specificphosphodiesteraseRD1preventsplasma membrane association and the attainment of enhanced thermostability without alteringits sensitivity toinhibition by Rolipram. Biochem J 1993;292:677-86.
16. Scotland G, Houslay MD. Chimeric constructs show that the unique N-terminal domain of the cyclic AMP phosphodiesterase RD1 (RNPDE4A1A; rPDE-IVA1) can confer membrane association upon the normally cytosolic protein chloramphenicol acety ltransferase. Biochem J 1995;308:673-81.
17. 2+-triggered membrane association with selectivity for interaction with phosphatidic acid. J Biol Chem 2002;277:28298-309.
18. Huston E, Houslay TM, Baillie GS, Houslay MD. cAMP phosphodiesterase-4A1 (PDE4A1) has provided the paradigm for the intracellular targeting of phosphodiesterases, a process that underpins compartmentalized cAMP signalling. Biochem Soc Trans 2006;34:504-9.
19. Rubin JB, Kung AL, Klein RS, et al. A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc Natl Acad Sci USA 2003;100:13513-8.
20. Smith MC, Luker KE, Garbow JR, et al. CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res 2004;64:8604-12.
21. Lois C, Hong EJ, Pease S, Brown EJ, Baltimore D. Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors. Science 2002;295:868-72.
22. Gross S, Piwnica-Worms D. Real-time imaging of ligand-induced IKK activation in intact cells and in living mice. Nat Methods 2005;2:607-14.
23. Kiehl EL, Stojadinovic S, Malinowski KT, et al. Conformal murine CNS radiotherapy using microRT. In: Toronto (ON): 15th International Conference on the use of Computers in Radiation Therapy; 2007.
24. Woerner BM, Warrington NM, Kung AL, Perry A, Rubin JB. Widespread CXCR4 activation in astrocytomas revealed by phospho-CXCR4-specific antibodies. Cancer Res 2005;65:11392-9.
25. Bender AT, Beavo JA. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 2006;58:488-520.
26. McPhee I, Cochran S, Houslay MD. The novel long PDE4A10 cyclic AMP phosphodiesterase shows a pattern of expression within brain that is distinct from the long PDE4A5 and short PDE4A1 isoforms. Cell Signal 2001;13:911-8.
27. McPhee I, Pooley L, Lobban M, Bolger G, Houslay MD. Identification, characterization and regional distribution in brain of RPDE-6 (RNPDE4A5), a novel splice variant of the PDE4A cyclic AMP phosphodiesterase family. Biochem J 1995;310:965-74.
28. Kleihues P, Burger PC, CollinsVP, Newcomb EW, Ohgaki H, Cavenee WK. Glioblastoma. In: Kleihues P, Cavenee WK, editors. World Health Organization classification of tumours: pathology and genetics of tumours of the central nervous system. Lyon: IARC Press; 2000.
29. Ishii N, Maier D, Merlo A, et al. Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol 1999;9:469-79.
30. Su X, Gopalakrishnan V, Stearns D, et al. Abnormal expression of REST/NRSF and Myc in neural stem/ progenitor cells causes cerebellar tumors by blocking neuronal differentiation. Mol Cell Biol 2006;26: 1666-78.
31. Sang UH, Banaie A, Rigby L, Chen J. Mutant p53 may selectively suppress glial specific proteins in pluripotential human neuroectodermal tumor cells. Neurosci Lett 1998;244:41-6.
32. Furman MA, Shulman K. Cyclic AMP and adenyl cyclase in brain tumors. J Neurosurg 1977;46: 477-83.
33. Racagni G, Pezzotta S, Giordana MT, et al. Cyclic nucleotides in experimental and human brain tumors. J Neurooncol 1983;1:61-7.
34. Warrington NM, Woerner BM, Daginakatte GC, et al. Spatiotemporal differences in CXCL12 expression and cyclic AMP underlie the unique pattern of optic glioma growth in neurofibromatosis type 1. Cancer Res 2007; 67:8588-95.
35. 2+. J Cell Sci 2006; 119:3799-810.
36. Anderson JA, Woodcock TM, Harty JI, Knott AW, Edwards MJ. The effects of oral pentoxifylline on interleukin-2 toxicity in patients with metastatic renal cell carcinoma. Eur J Cancer1995;31A:714-7.
37. Stewart DJ, Dahrouge S, Agboola O, Girard A. Cranial radiation and concomitant cisplatin and mitomycin-C plus resistance modulators for malignant gliomas. J Neurooncol 1997;32:161-8.
38. Zeller E, Stief HJ, Pflug B, Sastre-y-Hernandez M. Results of a phase II study of the antidepressant effect of Rolipram. Pharmacopsychiatry 1984;17:188-90.
39. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997-1003.
40. Chakravarti A, Erkkinen MG, Nestler U, et al. Temozolomide-mediated radiation enhancement in glioblastoma: a report on underlying mechanisms. Clin Cancer Res 2006;12:4738-46.
41. Nishiyama S, Okudaira M, Saito N. Mechanisms of Rolipram-induced increase in the incidence of mammary adenocarcinoma: histopathological study of a 104-week oral carcinogenicity study in female Sprague-Dawley rats. Arch Toxicol 2006;80:88-97.
42. Houslay MD, Schafer P, Zhang KY Keynote review: phosphodiesterase-4 as a therapeutic target. Drug DiscovToday 2005;10:1503-19.